Clinical trials: Meningococcal ACWY Disease
Infections, Meningococcal
Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination
The purpose/aim of this study is to assess the safety and antibody response to vaccination with a booster dose of Menveo given 4-6 years after primary MenACWY vaccination and to assess the safety and antibody response to a single…
- Trial name
- NCT02986854
- Testing
- Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 704 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease
Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older
A multicenter, single arm, postmarketing surveillance study. This study is a postlicensure requirement of the Philippine Food and Drug Administration (FDA) to provide continued safety evaluation of MenACWY-CRM in Philippine…
- Trial name
- NCT01705379
- Testing
- Novartis Meningococcal ACWY Conjugate Vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningitis, Septicemia
Understanding the Immune Response to Meningitis Vaccines
The purpose of the study is to evaluate and compare the immune response to two vaccines against 4 related bacteria: meningococcal serogroups A, C, W-135 and Y.
- Trial name
- NCT00901940
- Testing
- Meningococcal (Groups A, C, Y and W-135) Conjugate, Meningococcal polysaccharide A, C, Y and W135 and Menveo
- Where
- United Kingdom
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Meningococcal Disease, Infections, Meningococcal
Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.
This study was designed to conduct a comparative trial to further evaluate the safety, immunogenicity and antibody persistence of two doses of Novartis MenACWY conjugate vaccine, given 2 months apart, versus one dose of Novartis…
- Trial name
- NCT01682876
- Testing
- MenACWY-CRM
- Where
- 19 sites in United States
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease
Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age
Safety and immunogenicity of meningococcal ACWY conjugate versus polysaccharide vaccine in children 2 to 10 years of age
- Trial name
- NCT00329849
- Testing
- Meningococcal ACWY-CRM conjugate vaccine, Meningococcal ACWY-PS polysaccharide vaccine
- Where
- 3 sites in Argentina
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Infections, Meningococcal Meningitis
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
This study will evaluate the lot to lot consistency, safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine in healthy US adolescents and adults.
- Trial name
- NCT00450437
- Testing
- MenACWY CRM, Meningococcal ACWY Conjugate vaccine
- Where
- 40 sites in United States
- Volunteers
- 3,539 people
- Sponsor
- Novartis Vaccines
Meningococcal Disease, Meningococcal Meningitis
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea
This study is designed to evaluate the immunogenicity and the safety of a quadrivalent vaccine MenACWY-CRM in healthy subjects from 11 to 55 years of age in Korea.
- Trial name
- NCT01274897
- Testing
- Novartis MenACWY-CRM
- Where
- 8 sites in South Korea
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Meningitis
Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers
The primary immunogenicity objective is to assess and compare the immunogenicity of one dose of MenACWY to one dose of Menjugate given to healthy toddlers at 12 months of age as measured by the percentage of subjects with serum…
- Trial name
- NCT00667602
- Testing
- MenACWY-CRM197 (two doses), MenC, PCV7
- Where
- 28 sites in Germany
- Volunteers
- 662 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Disease
Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults
This study is aimed to evaluate safety, tolerability and immunogenicity of three doses of Novartis 4CMenB and of one dose of Novartis Meningococcal ACWY vaccine when administered to healthy at-risk adults.
- Trial name
- NCT00560313
- Testing
- Men ACWY CRM, 4CMenB
- Where
- Italy
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningitis, Meningococcal
Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine
The purpose of this study was to assess immunogenicity and safety of MenABCWY vaccine in healthy adolescents and adults aged 15 to 25 years previously vaccinated with MenACWY vaccine.
- Trial name
- NCT04707391
- Testing
- MenABCWY vaccine, MenACWY vaccine, MenB vaccine
- Where
- 69 sites in United States, Argentina and 2 more
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease, Meningococcal Meningitis
Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years
Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years
- Trial name
- NCT00329901
- Testing
- Meningococcal ACWY conjugate vaccine (MenACWY-CRM), Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)
- Where
- 14 sites in Italy
- Volunteers
- 1,072 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Disease, Meningococcal Meningitis
Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine
This study compares the safety and immunogenicity profile of combined hepatitis A/B vaccine given alone or concomitantly with MenACWY-CRM to healthy adults.
- Conditions
- Meningococcal Disease, Meningococcal Meningitis, Hepatitis A, Hepatitis B
- Trial name
- NCT01453348
- Testing
- MenACWY-CRM, Combined inactivated hepatitis A & recombinant hepatitis B, Recombinant hepatitis B vaccine
- Where
- 4 sites in Germany
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Disease
PRIME Follow up - Quadri Meningo Vacinees
A previous cohort of 93 clinical trial participants received quadrivalent meningococcal conjugate vaccine, which includes strains ACW and Y, in their teenage years.
- Trial name
- PRIMEfollowup (NCT02811120)
- Testing
- venepuncture only
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Public Health England
Meningococcal Infections
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
Safety immune response of Novartis MenACWY-CRM conjugate vaccine when given to healthy toddlers
- Trial name
- NCT00626327
- Testing
- MenACWY-CRM + MMRV, MMRV, MenACWY-CRM
- Where
- 90 sites in United States
- Volunteers
- 1,630 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal ACWY Disease
A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).
This study will evaluate the immunogenicity, reactogenicity and safety of a booster dose of MenACWY-TT vaccine administered 10 years after healthy subjects aged 11-17 years received either MenACWY-TT vaccine (Nimenrix) or…
- Trial name
- NCT03189745
- Testing
- MenACWY-TT
- Where
- Philippines
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- Pfizer
Bacterial Meningitis
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India
This study will evaluate the immunogenicity of a single injection of Novartis Meningococcal ACWY conjugate vaccine in healthy subjects from the age of 2 years and above in India.
- Trial name
- NCT01547715
- Testing
- Meningococcal ACWY conjugate vaccine
- Where
- 4 sites in India
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Novartis
Meningococcal Disease
B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
This study is aimed to assess whether the frequency of meningococcal serogroup A, C, W-135 and Y specific memory B Cells, measured 1 month after a primary vaccination series of Novartis MenACWY vaccine, predicts the specific…
- Trial name
- NCT00488683
- Testing
- MenACWY-CRM, DTaP-Hib-IPV, PCV
- Where
- United Kingdom
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
HIV/AIDS, Meningococcal Disease
Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study
The need for and timing of booster doses of meningococcal vaccines in People Living with HIV (PLWHIV) is currently unknown. As such it is impossible for clinicians to recommend booster doses or to know if and when these might be…
- Trial name
- NCT04239430
- Testing
- Serum Bactericidal Assays
- Where
- United Kingdom
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
Meningococcal Disease
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia
To evaluate the immune response and safety following a single dose of Novartis Meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy children, adolescents and adults in Russia.
- Trial name
- NCT01725217
- Testing
- MenACWY-CRM
- Where
- 4 sites in Russia
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Meningitis
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
The primary objective is to evaluate the persistence of bactericidal antibodies in adolescents previously enrolled in the V59P13 study who received either Novartis MenACWY Conjugate Vaccine or commercially available MenACWY…
- Trial name
- NCT00856297
- Testing
- MenACWY-CRM conjugate vaccine, Licensed comparator
- Where
- 32 sites in United States
- Volunteers
- 389 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines